Morpholino Pyrido[3,2-d]pyrimidine PI3K Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PI3K inhibitors, such as LY294002 and Wortmannin, are non-specific and do not distinguish among different PI3K isoforms, making it unclear which isoform is involved in specific diseases, and there is a need for selective inhibitors to better understand and target specific PI3K isoforms in diseases like autoimmune disorders and cancer.
Innovation Solution
Development of pyrido[3,2-d]pyrimidine derivatives, specifically morpholino pyrido[3,2-d]pyrimidine compounds substituted in positions 2, 6, and 8, which act as selective modulators of PI3Ks, including PI3K alpha, gamma, delta, or beta, to inhibit or modulate their activity in disease states.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific PI3K inhibitors (LY294002, Wortmannin) are used, then PI3K activity is inhibited, but isoform selectivity is lost
Solution Approach 1:
The patent applies local quality by introducing specific substitution patterns at positions 2, 6, and 8 of the pyrido[3,2-d]pyrimidine core, where each position provides localized structural features that interact with specific PI3K isoform binding sites. The morpholino group at position 2 and specific substituents at positions 6 and 8 create localized molecular characteristics that confer isoform selectivity while maintaining overall inhibitory activity.
Solution Approach 2:
The patent employs parameter changes by systematically varying the chemical structure parameters of the pyrido[3,2-d]pyrimidine derivatives, including the type of substituents (R1, R2, R3, R4), their positions, and stereochemistry. These parameter modifications allow fine-tuning of the compounds' binding affinity and selectivity toward specific PI3K isoforms while maintaining therapeutic efficacy.
2Measurement precision
If selective PI3K isoform inhibitors are developed, then isoform-specific targeting is achieved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the molecular structure into distinct functional segments: a core pyrido[3,2-d]pyrimidine scaffold and separate substituent groups at positions 2, 6, and 8. Each segment can be independently optimized for its specific function (binding affinity, selectivity, pharmacokinetics), allowing complex selectivity requirements to be met through modular design rather than monolithic structural complexity.
Data Source
AI summary
This invention relates to compounds of Formula (I) as Pi3k inhibitors for treating autoimmune deseases, inflammatory disorders, multiple sclerosis and other deseases like cancers.